Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Digestive & weight
What oral forms of KPV exist?
KPV capsules lack human data: FDA found none by any route, and oral KPV studies used colitis mice dosed through drinking water or engineered carriers.
Quick answer
KPV is marketed in single-ingredient oral products, and websites also promote multi-peptide products that pair KPV with BPC-157. KPV is not part of any FDA-approved drug and has no established labeled route. FDA's 2026 review found no human exposure data for KPV by any route. Oral studies used mice with colitis and tested no capsule. In those mice, a modified KPV prodrug reached 3.8-fold greater colon accumulation than free KPV. KPV falls under WADA's class of non-approved substances, prohibited at all times in sport.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Oral KPV is marketed alone and in peptide combinations
KPV, short for lysine-proline-valine, is marketed in single-ingredient products taken by mouth1. Websites also promote multi-ingredient products that pair it with peptides such as BPC-157. Published KPV findings come from laboratory and animal research. FDA's April 2026 update identified no human exposure data for KPV2 by any route.
KPV is a three-amino-acid fragment from the end of alpha-melanocyte-stimulating hormone3. No FDA-approved drug contains KPV. FDA evaluated KPV free base and KPV acetate as different active pharmaceutical ingredients1.
With no approved standard, each oral KPV product is judged on its own details.
What to check on an oral KPV product
Oral KPV products differ by chemical form, ingredient mix, manufacturing, and storage. Each difference changes how far the published KPV research applies to a product.
Oral KPV is a peptide product. Peptides can be extremely sensitive to formulation and environmental conditions1. Swallowed peptides also face breakdown by digestive enzymes4 and cross the gut lining poorly. The result is low bioavailability, meaning a small share of the dose reaches the bloodstream.
| Form | What to check |
| Single-ingredient KPV capsule | The form named on the label (KPV free base or KPV acetate); the labeled amount; prescription compounding or supplement labeling; storage and stability information; and any coating or absorption-support ingredient |
| Combination product (KPV with BPC-157 or another peptide) | The route the product is made for, each peptide's form and amount, and whether any study tested that exact combination |
Several oral KPV studies have tackled those same barriers by packaging KPV in engineered carriers.
What has oral KPV research used?
Oral KPV research has used mice with colitis, an inflamed colon. Those mice got KPV in drinking water or in engineered carriers. None of those studies tested a capsule.
- Drinking water: colitis mice drinking plain KPV had less colitis and lower expression of inflammatory cytokines5 (immune signaling proteins)
- Nanoparticles in a hydrogel: KPV nanoparticles in an alginate-chitosan gel eased mouse colitis at a far lower concentration6 than free KPV
- Coated nanoparticles: hyaluronic acid-coated KPV nanoparticles lowered the cytokine TNF-α more than uncoated ones7 in mice with ulcerative colitis
- Prodrug conjugate: proKPV, a modified KPV built for oral delivery, reached 3.8-fold greater colon accumulation than free KPV8 in colitis mice
Each oral KPV result reflects its own delivery method and the mouse colon. None describes a plain capsule taken by a person.
How does oral KPV compare with other routes?
No human study compares oral KPV with other routes. FDA's 2026 review found no human pharmacokinetic studies1 of KPV by any route. Those studies measure absorption and clearance.
In human intestinal cell lines, KPV entered cells through PepT15. That transporter carries two- and three-amino-acid peptides9. Whether an intact peptide then reaches the blood is highly variable and structure-dependent10. Gut-cell uptake alone does not show KPV reaching circulation.
On donated human skin in a lab, KPV alone did not pass through detectably3. Microneedles (tiny skin-piercing needles) or a mild electric current increased KPV passage. In rats with colitis, a rectal KPV gel eased colon inflammation11. Plain KPV solution was unstable. In rats with chemotherapy-related mouth sores, a KPV gum gel aided tissue repair12. That gel was applied in the mouth, not swallowed.
Research or experience with one route does not automatically describe another.
KPV falls under the World Anti-Doping Agency (WADA) class of non-approved substances, prohibited at all times13. That class covers substances with no government approval for human therapeutic use. Athletes subject to drug testing can face sanctions for using KPV. Check current WADA and league rules before considering it.
Getting KPV in 2026
Superpower will offer KPV formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will assess whether KPV fits each person's health care. The Superpower peptide waitlist is open now.
KPV itself is not an FDA-approved drug. The Department of Health and Human Services stated in October 2026 that it does not intend to take enforcement action14 against state-licensed pharmacies compounding certain peptides while the 503A Bulks List, the roster of ingredients pharmacies may use in compounding, is finalized. That interim policy names KPV alongside five other peptides15 and sets conditions that include ingredients from FDA-registered facilities and a patient-specific prescription. Before it, a July 2026 FDA advisory committee recommended adding KPV to the list16, and the rulemaking remains in progress.